These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30301414)

  • 1. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
    Reiman T; Savage KJ; Crump M; Cheung MC; MacDonald D; Buckstein R; Couban S; Piliotis E; Imrie K; Spaner D; Shivakumar S; Kuruvilla J; Villa D; Shepherd LE; Skamene T; Winch C; Chen BE; Hay AE
    Leuk Lymphoma; 2019 Apr; 60(4):912-919. PubMed ID: 30301414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
    Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
    Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
    Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
    Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
    Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
    Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
    Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
    Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
    Hapgood G; Stone JM; Zannino D; George A; Marlton P; Prince HM; Hui CH; Prosser I; Lewis ID; Bradstock K; Seymour JF;
    Leuk Lymphoma; 2019 Apr; 60(4):904-911. PubMed ID: 30547695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Balzarotti M; Magagnoli M; Canales MÁ; Corradini P; Grande C; Sancho JM; Zaja F; Quinson AM; Belsack V; Maier D; Carlo-Stella C
    Invest New Drugs; 2021 Aug; 39(4):1028-1035. PubMed ID: 33523334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Holkova B; Yazbeck V; Kmieciak M; Bose P; Ma S; Kimball A; Tombes MB; Shrader E; Wan W; Weir-Wiggins C; Singh A; Hogan KT; Conine S; Sankala H; Roberts JD; Shea TC; Grant S
    Leuk Lymphoma; 2017 Jun; 58(6):1349-1357. PubMed ID: 28103725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
    Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
    Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.